Vinehealth, an award-winning platform to improve the quality of life and survival of cancer patients through highly personalised patient support, has secured a £1m Biomedical Catalyst grant to deliver its innovative cancer companion app to four NHS trusts within a randomised controlled trial, thus generating robust evidence of the platform’s clinical and cost effectiveness in improving patient self-management and data collection.
Since the company’s launch in 2019, Vinehealth has had many incredible achievements. One of the most notable was being announced as the highest rated cancer app in the world by leading organisation ORCHA, where Vinehealth scored 93%, over 10% higher than any other cancer tool. In 2020, Vinehealth was a winner of the NHSx Techforce19 grant, partnering with The Royal Marsden, a world-leading cancer centre to fulfil the scope of supporting the mental health and well-being of cancer patients during the COVID-19 pandemic. Vinehealth works with the UK’s leading charities, such as CRUK, Macmillan and Bowel Cancer UK, whose invaluable supportive content features in the app.
The Vinehealth app enables cancer patients to better self-manage their medications, side-effects, symptoms and lifestyles, seamlessly integrating with smartphones and wearables. Patients can regularly enter outcome data to support clinical decision-making, inform service delivery and drive clinical research.
Vinehealth’s CEO, Rayna Patel, says:
“Providing remote patient support and enabling clinicians to understand how their patients are doing remotely is crucial in a post-pandemic world. Vinehealth is at the forefront of this shift and we are delighted to be recognised in the way by Innovate UK”. Innovate UK received 373 submitted applications, approximately triple the usual number, and were able to fund 18 projects. The lowest score of the funded project was 60%, with Vinehealth scoring a phenomenal 86.8% – a fantastic achievement for the Vinehealth team.”
News & Analysis